We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
178 result(s) found, displaying 21 to 30
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OPDUALAG nivolumab 240mg and relatlimab 80mg in 20mL concentrate solution for IV infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CAMZYOS mavacamten 10 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CAMZYOS mavacamten 5 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CAMZYOS mavacamten 2.5 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CAMZYOS mavacamten 15 mg capsule blister pack.
-
Australian public assessment report (AusPar)AusPAR for Sotyktu (deucravacitinib) for treatment of adult patients with moderate-to-severe plaque psoriasis.
-
Australian public assessment report (AusPar)AusPAR for Camzyos (mavacamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ONUREG azacitidine 200 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ONUREG azacitidine 300 mg film-coated tablet blister pack.
-
Australian public assessment report (AusPar)AusPAR for Opdivo (nivolumab) for the treatment of adjuvant treatment of patients with muscle invasive urothelial carcinoma (MIUC).